Brammer Bio Partners in Gene TherapyBy
Brammer Bio, a Lexington, Massachusetts-headquartered cell and gene therapy contract development and manufacturing organization, has partnered with Abeona Therapeutics, a Dallas, Texas-headquartered clinical-stage biopharmaceutical company, to manufacture a gene therapy injectable drug, ABO-102 with plans for commercial translation.
ABO-102 is a first-in-man clinical trial using a single intravenous injection of adeno-associated virus (AAV) gene therapy for subjects with Sanfilippo syndrome, a rare autosomal-recessive lysosomal storage disease.
Brammer Bio is providing process development and clinical vector supply.
Source: Abeona Therapeutics